The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a preclinical CD19 autoimmune program. BMS established itself as a major player in the cell therapy market by acquiring Celgene in 2019. The deal covered autologous CAR-T cell therapies that originated at bluebird bio and Juno Therapeutics. Since then, the idea of triggering the production of CAR-T cells in patients, rather than engineering cells outside of the body, has gained more and more traction.
Read the full article: BMS Inks $1.5B In Vivo Car-T Buyout to Pull Orbital into Its Sphere of Influence //
Source: https://www.fiercebiotech.com/biotech/bms-inks-15b-vivo-car-t-buyout-pull-orbital-its-sphere-influence